Monday, May 08, 2023 3:11:12 PM
REPORT #17 (2023) For Week Ending 4/28/2023.
Thanks once again to @rafunrafun for providing the script data.
You can find the weekly Executive Summary Reports for 2022 here.
https://drive.google.com/drive/folders/1m8IHsRtEk7kroVbyNBjNFBnBn9GCyadH?usp=sharing
You can find the weekly Executive Summary Reports for 2023 here.
https://drive.google.com/drive/folders/1xCoxH36V_kok_z4egNiOG0eFe4WQ6IG-?usp=sharing
You can find this week’s Report (04/28/2023) here.
https://drive.google.com/file/d/1rOEl8VnfuRAwdgv2XjSkJAAZUQhE3jLU/view?usp=sharing
Summary: Total OMG-3 Market continues higher this week (175,274 vs 173,130) the previous week. The GV + V Market was also stronger, standing at 108,120 vs. 107,300 (slides 1 & 2). All generics and Lovaza/GLV were up except ApoTex (see slide #8).
VASCEPA® Continues above the trend line while generics continue below the trend line (see Slide #3).
Recent AMRN News
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
